Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Sales (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Return on Sales for 13 consecutive years, with 2.44% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 78.0% to 2.44% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.22% through Dec 2025, up 137.0% year-over-year, with the annual reading at 0.98% for FY2025, 114.0% up from the prior year.
  • Return on Sales for Q4 2025 was 2.44% at Theravance Biopharma, up from 0.18% in the prior quarter.
  • The five-year high for Return on Sales was 74.46% in Q3 2022, with the low at 2.12% in Q1 2023.
  • Average Return on Sales over 5 years is 4.29%, with a median of 0.37% recorded in 2021.
  • The sharpest move saw Return on Sales surged 7290bps in 2022, then plummeted -7503bps in 2023.
  • Over 5 years, Return on Sales stood at 1.72% in 2021, then tumbled by -85bps to 0.27% in 2022, then plummeted by -282bps to 0.48% in 2023, then skyrocketed by 442bps to 1.66% in 2024, then skyrocketed by 47bps to 2.44% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 2.44%, 0.18%, and 2.09% for Q4 2025, Q3 2025, and Q2 2025 respectively.